α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells

Cancer Letters

Volumn 335, Issue 2, 2013, Pages 472-478

  Michikoshi, Hiromitsu ^a   Nakamura, Takahiro ^a   Sakai, Katsuya ^a   Suzuki, Yoshinori ^a   Adachi, Eri ^a   Matsugo, Seiichi ^a   Matsumoto, Kunio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Lipoic acid; EGF; Growth factor; HGF; Lung cancer; Met; Receptor tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR RECEPTOR; THIOCTIC ACID;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; DOSE RESPONSE; ENANTIOMER; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTIOXIDANTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; THIOCTIC ACID;

EID: 84878263590     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.03.008     Document Type: Article

References (32)

1. Reed L.J. A trail of research from lipoic acid to α-keto acid dehydrogenase complexes. J. Biol. Chem. 2001, 276:38329-38336.
2. Bilska A., Wlodek L. Lipoic acid - the drug of the future?. Pharmacol. Rep. 2005, 57:570-577.
3. Yang Y.S., Frey P.A. 2-Ketoacid dehydrogenase complexes of Escherichia coli: stereospecificities of the three components for (R)-lipoate. Arch. Biochem. Biophys. 1989, 286:465-474.
4. Oehring R., Bisswanger H. Incorporation of the enantiomers of lipoic acid into the pyruvate dehydrogenase complex from Escherichia coli in vivo. Biol. Chem. 1992, 373:333-335.
5. Bast A., Haenen G.R. Interplay between lipoic acid and glutathione in the protection against microsomal lipid peroxidation. Biochim. Biophys. Acta 1988, 963:558-561.
6. Scholich H., Murphy M.E., Sies H. Antioxidant activity of dihydrolipoate against microsomal lipid peroxidation and its dependence on α-tocopherol. Biochim. Biophys. Acta 1989, 1001:256-261.
7. Packer L., Tritschler H.J., Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic. Biol. Med. 1997, 22:359-378.
8. Lee T., Dugoua J.J. Nutritional supplements and their effect on glucose control. Curr. Diab. Rep. 2011, 11:142-148.
9. Henriksen E.J., Diamond-Stanic M.K., Marchionne E.M. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic. Biol. Med. 2011, 51:993-999.
10. Packer L., Kraemer K., Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001, 17:888-895.
11. Na M.H., Seo E.Y., Kim W.K. Effects of α-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells. Nutr. Res. Pra. 2009, 3:265-271.
12. Kip1-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells. Eur. J. Pharmacol. 2010, 641:29-34.
13. Selvakumar E., Hsieh T.C. Regulation of cell cycle transition and induction of apoptosis in HL-60 leukemia cells by lipoic acid: role in cancer prevention and therapy. J. Hematol. Oncol. 2008, 1:4.
14. van de Mark K., Chen J.S., Steliou K., Perrine S.P., Faller D.V. Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J. Cell Physiol. 2003, 194:325-340.
15. Shi D.Y., Liu H.L., Stern J.S., Yu P.Z., Liu S.L. Alpha-lipoic acid induced ion hepatoma cells via the PTEN/Akt pathway. FEBS Lett. 2008, 582:1667-1671.
16. Simbula G., Columbano A., Ledda-Columbano G.M., Sanna L., Deidda M., Diana A., Pibiri M. Increased ROS generation and p53 activation in α-lipoic acid-induced apoptosis of hepatoma cells. Apoptosis 2007, 12:113-123.
17. Wenzel U., Nickel A., Daniel H. α-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2--generation. Apoptosis 2005, 10:359-368.
18. 2+. Ann. NY Acad. Sci. 2009, 1171:149-155.
19. Moungjaroen J., Nimmannit U., Callery P.S., Wang L., Azad N., Lipipun V., Chanvorachote P., Rojanasakul Y. Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation. J. Pharmacol. Exp. Ther. 2006, 319:1062-1069.
20. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
21. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., Nishiwaki Y., Saijo N., Ariyoshi Y., Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann. Oncol. 2007, 18:317-323.
22. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
23. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007, 98:1817-1824.
24. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale M.C., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Jänne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
25. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., Ogino H., Kakiuchi S., Hanibuchi M., Nishioka Y., Uehara H., Mitsudomi T., Yatabe Y., Nakamura T., Sone S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008, 68:9479-9487.
26. Wersto R.P., Chrest F.J., Leary J.F., Morris C., Stetler-Stevenson M.A., Gabrielson E. Doublet discrimination in DNA cell-cycle analysis. Cytometry 2001, 46:296-306.
27. Löffelhardt S., Bonaventura C., Locher M., Borbe H.O., Bisswanger H. Interaction of α-lipoic acid enantiomers and homologues with the enzyme components of the mammalian pyruvate dehydrogenase complex. Biochem. Pharmacol. 1995, 50:637-646.
28. Wojtalla A., Arcaro A. Targeting phosphoinositide3-kinase signaling in lung cancer. Crit. Rev. Oncol. Hematol. 2011, 80:278-290.
29. Whittaker S., Marais R., Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005.
30. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 2010, 10:760-774.
31. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
32. Yano S., Yamada T., Takeuchi S., Tachibana K., Minami Y., Yatabe Y., Mitsudomi T., Tanaka H., Kimura T., Kudoh S., Nokihara H., Ohe Y., Yokota J., Uramoto H., Yasumoto K., Kiura K., Higashiyama M., Oda M., Saito H., Yoshida J., Kondoh K., Noguchi M. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J. Thorac. Oncol. 2011, 6:2011-2017.